LadRx Goodwill
Goodwill of LadRx (LADX) as of Oct 24, 2026.
Get this data via API
Financial Data API
Goodwill
0.00USD
Last updated:
Goodwill of LadRx is 2018 0.00 USD. Goodwill of LadRx was 2017 - USD. It decreases by % lower compared to the previous year.
The LadRx Goodwill history
| YEAR | Goodwill | YoY |
|---|---|---|
| 0.00USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
LadRx Stock analysis
What does LadRx do? CytRx Corp. focuses on developing aldoxorubicin, a modified doxorubicin for cancer treatment, currently in Phase III trials for soft tissue sarcoma and multiple other cancer indications. The company generates revenue through clinical trial partnerships and potential future drug sales, targeting pharmaceutical companies and healthcare providers who require novel oncology treatments. CytRx's primary product, aldoxorubicin, is being evaluated in various cancer types including small cell lung cancer and glioblastoma, with additional pre-clinical development for DK049, an anti-cancer drug conjugate using LADR technology. The firm's revenue streams are derived from its clinical development programs and potential licensing agreements with partners in the oncology sector. LadRx is one of the most popular companies on Eulerpool.
Frequently Asked Questions about LadRx stock
On Eulerpool you can find the complete historical development of Goodwill LadRx since 2006 – with annual values, charts, and detailed analysis.
Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.
Goodwill's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's LadRx historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Balance Sheet — LadRx
Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets
All Key Metrics — LadRx
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth